Related Experiment Videos
Methylmalonic aciduria (cblF): case report and response to therapy
D J Waggoner1, K Ueda, C Mantia
1Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA. waggonervd@a1.kids.wustl.edu
American Journal of Medical Genetics
|October 21, 1998
Summary
Methylmalonic acidemia, a metabolic disorder, can stem from cobalamin issues. This study details a patient with the cblF complementation group, showing treatment outcomes.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Methylmalonic acidemia (MMA) is a rare genetic disorder.
- It can result from methylmalonyl CoA mutase deficiency or cobalamin (vitamin B12) metabolism defects.
- Cobalamin defects are classified into complementation groups (e.g., cblF).
Observation:
- A new patient presented with features of the cblF complementation group.
- This condition is characterized by elevated methylmalonic acid and homocysteine levels.
- The patient's clinical presentation and biochemical markers were monitored.
Findings:
- The patient exhibited elevated methylmalonic acid and homocysteine, consistent with the cblF defect.
- Treatment involved standard therapies and specific dietary restrictions.
- The patient's outcome in response to these interventions was evaluated.
Implications:
- This case highlights the clinical presentation and management of the cblF complementation group in methylmalonic acidemia.
- Understanding treatment responses in specific complementation groups is crucial for patient care.
- Further research into cobalamin metabolism defects can improve therapeutic strategies.